--- title: "Journey Medical (DERM) news: offering" url: "https://aibio.space/companies/journey-medical/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "DERM offering news: Journey Medical sets up new at-the-market program for 3,750,000 shares. Journey Medical Corporation (NASDAQ: DERM), United States." --- DERM Journey Medical Corporation NASDAQ · United States # Journey Medical (DERM) news DERM offering news Debt Financing · 2025-09-26 ## [Journey Medical extends SWK term loan maturity to June 2028 in credit agreement amendment](https://aibio.space/news/journey-medical-extends-swk-term-loan-maturity-june-2028-credit/) Journey Medical's $25.0 million SWK term loan now matures June 27, 2028. Principal repayments start in February 2026 unless trailing revenue tops $60.0 million at December 31, 2025. ## Latest Journey Medical news 1. 2025-08-28 Financings [Journey Medical sets up new at-the-market program for 3,750,000 shares](https://aibio.space/news/journey-medical-sets-up-new-market-program-3-750-000-shares/) Journey Medical signed an at-the-market sales agreement with B. Riley Securities, Inc. and Lake Street Capital Markets, LLC for up to 3,750,000 shares. It ended an older B. Riley program under which it had sold 4,121,318 shares. ## Journey Medical at a glance - **Ticker**: DERM - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $25.6 million ### Related companies - [Ionis Pharmaceuticals](https://aibio.space/companies/ionis-pharmaceuticals/) NASDAQ: IONS - [Shuttle Pharmaceuticals Holdings](https://aibio.space/companies/shuttle-pharmaceuticals/) NASDAQ: SHPH - [Accustem Sciences](https://aibio.space/companies/accustem-sciences/) OTC: ACUT - [Syros Pharmaceuticals](https://aibio.space/companies/syros-pharmaceuticals/) OTC: SYRS - [Nano Mobile Healthcare](https://aibio.space/companies/nano-mobile-healthcare/) OTC: VNTH - [AEON Biopharma](https://aibio.space/companies/aeon-biopharma/) AMEX: AEON - [Genprex](https://aibio.space/companies/genprex/) NASDAQ: GNPX - [TherapeuticsMD](https://aibio.space/companies/therapeuticsmd/) NASDAQ: TXMD ### Also on NASDAQ - [Cerenome](https://aibio.space/companies/cerenome/) CNSY - [CVRx](https://aibio.space/companies/cvrx/) CVRX - [NRC HEALTH](https://aibio.space/companies/nrc-health/) NRC - [Precigen](https://aibio.space/companies/precigen/) PGEN - [Upstream Bio](https://aibio.space/companies/upstream-bio/) UPB - [Innoviva](https://aibio.space/companies/innoviva/) INVA ## What Journey Medical does Journey Medical Corporation is a commercial-stage pharmaceutical company that sells and markets FDA-approved prescription products for dermatological conditions through its field sales organization. Its current portfolio includes eight FDA-approved prescription drugs marketed in the U.S. Emrosi, a minocycline extended-release capsule for inflammatory lesions of rosacea in adults, was approved in November 2024, and the company began sales promotion in April 2025. Its other actively marketed products are Qbrexza, for primary axillary hyperhidrosis, Accutane, for severe recalcitrant nodular acne, and the topical minocycline foams Amzeeq and Zilxi. Legacy products include Exelderm and Targadox. Journey developed Emrosi in collaboration with Dr. Reddy's Laboratories, Ltd. The company acquires rights to products and product candidates by licensing or acquiring an ownership interest, funds their development, and commercializes them. Journey is a controlled subsidiary of Fortress Biotech, Inc. | Product or program | What it is | Stage | |---|---|---| | Emrosi | Minocycline extended-release capsule for inflammatory lesions of rosacea | approved in the US | | Qbrexza | Medicated cloth towelette for primary axillary hyperhidrosis | approved in the US | | Accutane | Oral isotretinoin for severe recalcitrant nodular acne | approved in the US | | Amzeeq | Topical minocycline foam for acne vulgaris | approved in the US | | Zilxi | Topical minocycline foam for rosacea inflammatory lesions | approved in the US | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm). ## Journey Medical annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$61.9 million](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/) | [$56.1 million](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/) | | Research and development | [$480,000](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/) | [$9.9 million](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/) | | Net income (loss) | [-$11.4 million](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/) | [-$14.7 million](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/) | | Cash from operations | [-$12.4 million](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/) | [-$9.1 million](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/) | | Cash and equivalents | [$24.1 million](https://www.sec.gov/Archives/edgar/data/1867066/000110465926094948/) | [$20.3 million](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $25.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Journey Medical Has Journey Medical raised money recently? Our latest story on this, dated Aug 28, 2025: "Journey Medical sets up new at-the-market program for 3,750,000 shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/journey-medical-sets-up-new-market-program-3-750-000-shares/). What is the ticker symbol of Journey Medical? Journey Medical Corporation trades under the ticker DERM on NASDAQ. Where is Journey Medical listed? Journey Medical Corporation is listed on NASDAQ. What is the SEC CIK of Journey Medical? The SEC Central Index Key (CIK) for Journey Medical Corporation is 1867066. Its filings are on SEC EDGAR. Which country or territory is Journey Medical listed under? Our directory records Journey Medical Corporation under United States. What does Journey Medical do? Our directory classifies Journey Medical Corporation as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Journey Medical? The ISIN recorded for Journey Medical Corporation is US48115J1097. Does aibio.space cover Journey Medical? aibio.space lists Journey Medical Corporation among 2,820 public biotech companies and publishes its news here as stories appear. Where is Journey Medical incorporated? SEC records list its state or country of incorporation as DE. What does Journey Medical develop? Journey Medical Corporation is a commercial-stage pharmaceutical company that sells and markets FDA-approved prescription products for dermatological conditions through its field sales organization. Its current portfolio includes eight FDA-approved prescription drugs marketed in the U.S. Emrosi, a minocycline extended-release capsule for inflammatory lesions of rosacea in adults, was approved in November 2024, and the company began sales promotion in April 2025. What is Emrosi from Journey Medical? Emrosi: Minocycline extended-release capsule for inflammatory lesions of rosacea Stage: approved in the US. What is Qbrexza from Journey Medical? Qbrexza: Medicated cloth towelette for primary axillary hyperhidrosis Stage: approved in the US. What was Journey Medical's revenue last year? $61.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Journey Medical profitable? Journey Medical Corporation reported a net loss of $11.4 million for the fiscal year ended Dec 31, 2025, and used $12.4 million of cash in operations, per its annual report to the SEC. How much does Journey Medical spend on research and development? $480,000 in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Journey Medical Members talk about Journey Medical (DERM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Journey Medical, newest first. Each line links the filing it comes from. 1. 2026-03-26 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm) 2. 2026-01-15 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1867066/000110465926004131/tm2534369d2_s3.htm) 3. 2025-08-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1867066/000110465925084879/tm2524202d2_8kseq1.htm) 4. 2025-03-27 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1867066/000141057825000490/derm-20241231x10k.htm) 5. 2025-02-05 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 2.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1867066/000110465925009641/tm255603d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:DERM on TradingView](https://www.tradingview.com/symbols/NASDAQ-DERM/). ## SEC filings and registration - **SEC name**: Journey Medical Corp - **CIK**: 1867066 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: DERM (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company
Emerging growth company - **Business address**: 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE, AZ, 85258 - **Phone**: 480-434-6670 ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1867066/000110465926094948/derm-20260630x10q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1867066/000110465926094862/tm2622742d1_8k.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1867066/000110465926077888/tm2619038d1_8k.htm) filed 2026-06-26 - [10-Q](https://www.sec.gov/Archives/edgar/data/1867066/000110465926060297/derm-20260331x10q.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_8k.htm) filed 2026-05-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1867066/000110465926052883/tm261508-3_def14a.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1867066/000110465926046158/tm2612310d1_8k.htm) filed 2026-04-21 - [10-K](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm) filed 2026-03-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001867066), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Journey Medical Corporation is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DERM, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Journey Medical Corporation - **Ticker**: DERM - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US48115J1097 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-DERM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/journey-medical/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Journey Medical (DERM) news: offering", 2026-10-31, https://aibio.space/companies/journey-medical/